Teva Canada Announces New Autoinjector for AJOVY for the Preventive Treatment of Migraine in Adults - Seite 2

Migraine is a disabling chronic neurological disease that causes head pain so severe that sufferers often cannot function during an attack. Migraine reduces quality of life and disrupts migraineurs’ ability to perform daily activities.^5,6 It is among the top 10 causes of disability worldwide and the seventh cause of years of life lost to disability.^7,8,9 In Canada, migraine is most common in women and most common between the ages of 30 and 49.¹⁰ Migraine therefore reduces patients’ quality of life, ability to work, and overall productivity right at the prime of their life. While acute treatment modalities are used to treat migraine attacks when they occur, they do not prevent them. Novel treatments like AJOVY were specifically designed to actually prevent migraine from occurring.

AJOVY was evaluated in two pivotal Phase III clinical trials that enrolled patients with disabling migraine and studied fremanezumab as a prophylactic treatment. For patients with chronic migraine, 40.8 per cent taking the monthly dose and 37.6 per cent taking the quarterly dose experienced more than a 50 per cent reduction in monthly average headache days of at least moderate severity.¹¹ For patients with episodic migraine, 47.7 per cent taking the monthly dose and 44.4 per cent taking the quarterly dose experienced more than a 50 per cent reduction in monthly average number of migraine days.¹² The safety profile was also assessed.^1,2,3 AJOVY has been studied in patients with chronic or episodic migraine and was shown to significantly reduce patients’ mean monthly migraine days—with some patients achieving a 50% reduction or more.^1,2,3

About AJOVY

AJOVY (fremanezumab) is indicated for the preventive treatment of migraine in adults who have at least four migraine days per month. AJOVY is available as a 225 mg/1.5 mL single-dose injection in an autoinjector or prefilled syringe with two dosing options: 225 mg monthly, administered as one subcutaneous injection; or 675 mg every three months (quarterly), administered as three subcutaneous injections. AJOVY is intended for patient self-administration after the patient or their caretaker has been trained to administer the product. AJOVY patients and prescribers are supported by the AJOVY Teva Support Solutions Patient Support Program.